Tetra Bio-Pharma Inc. (OTCPK: TBPM.Q)
Health Care · Pharmaceuticals · CA
$0.00
— today · 0.0% 1Y
Tetra Bio-Pharma Inc. (OTCPK: TBPM.Q) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $516.00 and employs 33 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores Tetra Bio-Pharma Inc. across four factors: quality 9/100. Its strongest factor is quality.
TBPM.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $516.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.09
- Dividend yield
- —
- Beta (5Y)
- 31.82
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 515.63M
- Employees
- 33
- Next earnings
- —
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.
- ISIN
- CA88166Y1007
- Listed since
- Jul 10, 2018
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.